Frontiers in Oncology (Aug 2020)

First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations

  • Naval Daver,
  • Allyson Price,
  • Christopher B. Benton,
  • Keyur Patel,
  • Weiguo Zhang,
  • Marina Konopleva,
  • Naveen Pemmaraju,
  • Koichi Takahashi,
  • Michael Andreeff,
  • Gautam Borthakur

DOI
https://doi.org/10.3389/fonc.2020.01538
Journal volume & issue
Vol. 10

Abstract

Read online

The prognostics implications of patients with acute myeloid leukemia harboring non-canonical FLT3 is unknown. The use of tyrosine kinase inhibitors in this patient population has not been previously reported. We report successful targeted therapy against non-ITD, non-D835 driver FLT3 alterations in two patient case studies with acute myeloid leukemia.

Keywords